The mechanisms and pathways for the control of food intake and body weight represent one of the most active areas of contemporary biomedical research, and might indicate new pathophysiological and pharmacological targets for eating disorders.
Obesity, bulimia, and anorexia nervosa are prevalent disorders in Western countries that are associated with significant morbidity and mortality. 1 Thus, prevention and treatment of these disease states would have important public health implications. However, efforts towards prevention and treatment of these conditions require a better understanding of the mechanisms responsible for energy homeostasis and body weight regulation. It is well known that despite frequent and sometimes marked fluctuations in energy intake and expenditure, body weight and adipose stores remain remarkably stable over prolonged periods of time, indicating that body adiposity is regulated by a controlled feedback system. It is also well known that hypothalamic centers play a central role in the regulation of energy homeostasis, a fact originally proven based on data derived from experimental disruption of certain hypothalamic areas and later from intracerebroventricular injection of orexigenic or anorexigenic neurotransmitters. 2 Our understanding of this physiological fact was recently greatly advanced by the discovery and further study of leptin, the product of the ob gene 3 which serves as the signal responsible for linking adipose stores with hypothalamic centers in this feedback loop that regulates energy homeostasis and body weight. Study of the peripheral and hypothalamic actions of leptin has revealed several exciting aspects of this complex neuroendocrine control system.
Leptin secretion and action
Leptin is secreted by the adiopose tissue and the placenta, 4 displays significant circadian and ultradian rhythmicity, 5 and circulates bound to specific binding proteins. 6 Leptin conveys information to the brain on the amount of energy stored as fat 7 and acts by binding to its receptor in the hypothalamus and, thus, activating the JAK-STAT signal transduction pathway in cerCorrespondence: C Mantzoros, MD, DSc, Division of Endocrinology, RN 324, Beth Israel Deaconess Medical Center, 99 Brookline Ave, Boston, MA 02215, USA. E-mail: cmantzorȰbih. harvard.edu tain hypothalamic centers. Food intake, neuroendocrine function, and energy expenditure, including motor activity and thermogenesis, are all altered by the binding of leptin in the hypothalamus. 8 Leptin is currently viewed as an important regulator of energy balance which acts to keep energy stores stable. Falling leptin in response to fasting results in adaptive neuroendocrine and metabolic responses, including decreased thyroid hormone levels that conserve energy, increased corticosteroid levels that result in mobilization of energy stores away from fat, and diminished reproductive capacity. All of these neuroendocrine changes are teleologically appropriate responses to increase survival and limit procreation in periods of starvation. 9 In contrast, leptin levels are increased in most cases of human obesity, 7 indicating an underlying leptin resistance. Although a defect in the blood-brain barrier transport system has been considered responsible for this leptin resistance, 10 defects in the sites of leptin action in the central nervous system (CNS) have also been proposed. 2, 4 Finally, mutations in either the leptin or the leptin receptor gene result in morbid obesity and neuroendocrine dysfunction not only in rodents but also in humans. 4, 11 Since leptin has important physiological roles in both starvation and obesity, the molecular targets of leptin action in the brain and leptin's complex network of interactions are currently the focus of intensive research efforts.
Leptin and hypothalamic neuropeptides
Leptin receptors have been found in several regions of the brain. These include the cerebellum, cortex, hippocampus, thalamus, choroid plexus and brain capillary endothelium in addition to the hypothalamus. 2, 4 The long and active receptor isoform, however, is mainly expressed in the arcuate, dorsomedial, ventromedial and paraventricular nuclei of the hypothalamus, where leptin's actions are exerted most rapidly and intensely. 2, 12 In these nuclei leptin alters the expression of several classical neuropeptides such as NPY, TRH and CRH as well as novel neuropeptides including urocortin, agouti-related peptide (AGRP) and melanin-concentrating-hormone (MCH) (see Image section). The best studied neuropeptides are NPY in the arcuate nucleus 2, 11, 13, 14 and TRH and CRH in the paraventricular nucleus. 2, [15] [16] [17] However, important new data on the interactions between leptin and several other neuropeptides accumulate rapidly 18 and will briefly be reviewed below.
The orexigenic neuropeptide NPY has been implicated in a wide range of actions including regulation of food intake and energy expenditure, cardiovascular and neuropsychological function as well as activation of several neuroendocrine axes.
14 NPY is considered to be the major mediator of leptin's actions in the arcuate nucleus. Recent experimental evidence suggests that NPY is increased in low leptin states, ie starvation, 9, 19 whereas leptin administration down-regulates NPY in the arcuate nucleus. This, in turn, results in a reduction of food intake, increase in the activity of the sympathetic nervous system and increase in energy expenditure as well as alteration of the peripheral metabolic milieu. 2, 9, 18 Injection of NPY centrally results in hyperphagia, decreased thermogenesis, and insulin resistance, ie characteristics of leptin-deficient conditions. [18] [19] [20] [21] Importantly, the severe obesity of leptin-deficient mice (ob/ob mice) is attenuated, but not completely corrected, by NPY deficiency. [18] [19] [20] [21] In addition, experiments using NPY knockout as well as NPY receptors Y1 and Y5-deficient mice, reveal that these mice do not develop significant disturbances in daily food intake and body weight, indicating that hypothalamic control of feeding is redundant. Since NPY is by no means the only mediator of leptin's actions in the brain, other potential targets of leptin in the hypothalamus have been agressively sought.
Recent data indicate that in addition to NPY, proopiomelanocortin (POMC) is also downstream of leptin in the pathway regulating energy homeostasis, as may be the products of the fat tub and Ay genes. 2, 14, 18, 22 Arcuate nucleus neurons containing POMC express Y1 NPY receptors and project to the PVN where they exert a net inhibitory effect on food intake. Leptin positively regulates POMC mRNA expression in the arcuate nucleus and upregulation of POMC results in increased production of a-MSH. This anorexigenic peptide produced by POMC is an agonist to the melanocortin 4 receptors (MC3 and 4). 2 Interestingly, leptin downregulates expression of another peptide in the arcuate nucleus; the agoutirelated peptide (AGRP). 23 AGRP acts as an antagonist to a-MSH at the MC3, MC4 melanocortin receptor level leading to obesity. 14, 18, 23, 24 Leptin-deficient ob/ob mice have decreased hypothalamic NPY and AGRP levels. Decreased leptin levels in response to fasting have recently been associated with similar changes of hypothalamic neuropeptides that are reversed by exogenous leptin administration. 9, 18, 23, 24 These findings from animal experiments were recently confirmed by studies on the first family of humans with a mutation of the POMC molecules. This mutation causes obesity, adrenal insufficiency and red hair pigmentation, 25 indicating that leptin and the POMC-a-MSH/AGRP system is important for body weight and energy homeostasis. Thus, leptin couples changes in energy balance and/or adipose stores to the appropriate hypothalamic response by altering the expression of hypothalamic neuropeptides. Indeed, leptin receptors are expressed by both POMC and NPY neurons in the arcuate nucleus. 19 Moreover, recent experimental evidence indicates that NPY and POMC are expressed in adjacent but distinct subpopulations of arcuate nucleus neurons, while certain NPY neurons coexpress the endogenous melanocortin antagonist AGRP. 19 Thus, it has been suggested that a unique cell type of hypothalamic neurons releases NPY and AGRP simultaneously in response to falling leptin levels. This, coupled with decreased release of anorexigenic neuropeptides elicits a robust compensatory response to fasting that results in increased food intake, maintenance of energy homeostasis and stability of adipose stores.
Targets of leptin in the hypothalamus other than melanocyte-stimulating hormone (a-MSH), its competitive antagonist agouti-related protein (AGRP), and proopiomelanocortin (POMC) include the newly discovered anorectic neuropeptide cocaine and amphetamine-related peptide (CART) 26 and melanin concentrating hormone (MCH). CART is a leptin-dependent hypothalamic neuropeptide that inhibits food intake, has been implicated in the psychological reward pathway and may be responsible for the markedly decreased appetite in drug addicts. 26 MCH acts on the melanosomes to regulate skin color and antagonizes the effect of a-MSH on skin pigment. Similar to their opposing actions in the skin, MCH and a-MSH are also functional antagonists in the hypothalamus, but in contrast to a-MSH and AGRP which are antagonists acting on the same receptor, MCH acts via an as-yet-unidentified receptor to increase food intake.
2 Although leptin appears to regulate CART and MCH expression, the physiological significance of this action is not clear and much work is needed to elucidate the role of CART and MCH and their interactions with other neuropeptides. For example, physiological characterization of knock out or transgenic mice overexpressing MCH and CART may provide important information and is expected with great interest.
Another neuropeptide that has recently attracted the attention of investigators is CRH. Both CRH and the CRH-like neuropeptide urocortin inhibit food intake and CRH has been found to stimulate energy expenditure and sympathetic nervous system activity. 27 Leptin receptors are expressed in CRH-containing neurons and leptin induces expression of CRH in the PVN. 28, 29 Recent evidence also indicates that leptin may affect food intake via CRH-receptor mediated pathways. 28 However, although CRH and/or urocortin are important for the effect of leptin on food intake, it appears that these neuropeptides act in conjunction with other neuropeptides implicated in appetite regulation. 28 All the above mentioned neuropeptides are mainly expressed in the arcuate nucleus, the DMH and PVN.
In contrast, a recently discovered family of neuropeptides, the orexins, were found to be expressed in the dorsolateral hypothalamus, 18 ,23 a hypothalamic area long suspected to play an important role in appetite regulation. Like hypothalamic NPY, orexin mRNA levels appear to increase with fasting and acute administration of orexin markedly stimulates food intake, but these findings need to be replicated. Although the effect of long-term administration of orexins has not yet been studied and their interactions with other neuropeptides remain to be elucidated, it is likely that orexins are a major family of appetite-regulating neuropeptides. The relationship between leptin and other hypothalamic neuropeptides, such as the tubby transcript, neurotensin and CCK has only now begun to be deciphered. The exact expression loci of all of these neuropeptides, the projections of cells expressing these neuropeptides throughout the brain and the potential functional interaction between these molecules are the focus of much scientific attention.
Elucidation of this complex network of interactions provides not only a working model for understanding the feedback system that regulates energy homeostasis but may also explain several genetic models of obesity in rodents. Thus, the obesity of leptin-deficient ob/ob and leptin-resistant db/db mice is likely to occur due to increased NPY and AGRP as well as decreased POMC and melanocortin signaling. In contrast, in the yellow obese or agouti mouse model of obesity the leptin system is not defective. However, ectopic production of agouti protein antagonizes the melanocortin receptors and results in obesity. Knock out of the melanocortin receptors results in a phenotype similar to that of the agouti mouse or mice with transgenic overexpression of the agouti-related protein. 30 Deletion and overexpression of other neuropeptides is now being performed and the results of these experiments are awaited with great interest.
Leptin and neuroendocrine function

Leptin and the CRH-ACTH-adrenal axis
In addition to its direct effect on the expression of the above orexigenic/anorexigenic neuropeptides, accumulating evidence suggests that leptin also affects energy homeostasis by regulating neuroendocrine function. More specifically, leptin regulates the expression of TRH and CRH in the paraventricular nucleus, thus influencing the hypothalamic-pituitarythyroid and adrenal axes. Initially, animal experiments demonstrated that leptin inhibits the starvationinduced activation of the ACTH-adrenal axis in vivo, 9 and later, in vitro studies indicated that leptin inhibits the hypoglycemia-induced CRH secretion by perifused hypothalami. 31 These observations in animals linking leptin with the CRH-ACTH-adrenal axis were consequently extended to humans. First, studies in healthy adults demonstrated that leptin's circadian and ultradian rhythmicity is significantly and inversely related to that of cortisol and ACTH. 5 In addition, it was recently shown that patients with leptin receptor mutations leading to obesity have adrenal insufficiency also. 11 Based on these converging lines of evidence, it appears that leptin influences not only energy homeostasis but also neuroendocrine function by altering the expression of CRH, a neuropeptide that regulates appetite, behavioral arousal and the hypothalamic-pituitary-adrenal axis.
Leptin and the TRH-thyroid axis
Similar to its effect on CRH, leptin appears to regulate TRH levels in PVN. Falling leptin levels in response to starvation have been associated with decreased TSH and triiodothyronine levels, while exogeneous administration of leptin to starving mice blunts the thyroid axis abnormalities associated with falling leptin levels. 9 Further experiments have indicated that this action of leptin is probably exerted at the level of the hypothalamus, since leptin administration prevents the fasting-induced suppression of TRH expression in rodent hypothalamus. 32 Importantly, in patients with leptin deficiency due to a homozygous mutation of the leptin receptor, thyrotropin secretion is reduced. 11 Thus, it appears that leptin, by signaling the status of energy stores to the brain, is a major mediator of the thyroid axis response to food deprivation which has teleologic implications since falling thyroid hormone levels may decrease metabolic requirements.
Leptin and the reproductive axis
In addition to its effect on CRH and TRH, leptin appears to affect the GnRH-gonadal axis. More specifically, it has been shown that leptin may alter the function of hypothalamic explants and influence LH secretion by pituitary cells. 8, 15 In vivo experiments have shown that leptin mediates the LH-gonadal changes in response to starvation in mice. 9 Leptin administration accelerates the onset of puberty in prepubertal mice and restores the fertility of infertile leptin-deficient ob/ob mice. 33 Increasing leptin levels may also be the factor that triggers puberty in humans, 34 and patients with leptin deficiency due to a homozygous mutation of the leptin receptor have no pubertal development. 11 We found that leptin may regulate the minute-to-minute oscillations in the levels of LH and estradiol and that the nocturnal rise of leptin may determine the changes in nocturnal LH profile in normal women. 35 This can explain the disruption of hypothalami-pituitary-gonadal function which is characteristic of low leptin states, such as cachexia and anorexia nervosa. 35 Indeed, the low leptin levels observed in anorexia nervosa 36, 37 are responsible for the abnormal menstrual function in these women 8 and increasing leptin levels in response to treatment are associated with increasing gonadotropin levels. 38 Thus low leptin levels convey to the brain information about inadequate energy reserves and result in a teleologically appropriate suppression of the LH-gonadal axis that would limit procreation.
Leptin and the growth hormone axis
Experimental data suggest that leptin is a metabolic signal that regulates growth hormone secretion. Although leptin administration to fed rodents does not alter growth hormone secretion, administration to fasted rodents restores the fasting-induced abnormal growth hormone secretion. 39 The role of leptin in regulating the secretion of growth hormone was recently confirmed in humans since patients with leptin deficiency due to a homozygous mutation of the leptin receptor have reduced growth hormone secretion in addition to early onset obesity. 11 However, the association between leptin and the growth hormone system in humans is complex and needs further study.
Future directions
The study of leptin and its effectors in the hypothalamus has already provided important insights into the mechanisms regulating energy homeostasis and the pathophysiology of eating disorders. All these disorders have proven to be far more complex than monogenic abnormalities. As leptin and the above mentioned neuropeptides are probably not the only important regulators of energy homeostasis, future research is expected to identify and study new molecules, such as the uncoupling proteins, 40, 41 which are downstream effectors of leptin, as well as molecules that either interact with the leptin system or act independently of the leptin system in energy homeostasis. Importantly, recent evidence indicates that the serotonin pathway for regulation of energy homeostasis, a target of a well studied class of anti-obesity agents, appears to be independent of the leptin system. 42 Genetic models involving the newly discovered neuropeptides are expected to be developed, and later combined to produce models of gene interactions in vivo. Study of these models under different conditions of diet, starvation and stress may provide important insights with respect to the interplay of several hypothalamic neuropeptides in regulating feeding as well as the interaction of genetics and environment in the regulation of energy homeostasis. Finally, development of leptin analogues as well as agonists and antagonists for hypothalamic neuropeptides will provide important information on the physiology of energy homeostasis and may lead to the development of new therapeutic strategies for the treatment of obesity and related disorders. Uncovering leptin's actions in the brain as well as gaining a working model of the effects of environmental factors such as stress and nutrition on the leptin system will hopefully allow for large advances in treatment and prevention of eating disorders and obesity.
